Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 6, 2010, Pages 673-678

  Kang, Hyun Seung ^a   Kim, Jin Hyun ^b   Phi, Ji Hoon ^a,c   Kim, Young Yim ^a   Kim, Jeong Eun ^a   Wang, Kyu Chang ^a,c   Cho, Byung Kyu ^a,c   Kim, Seung Ki ^a,c  

^a Seoul National University   (South Korea)

^b Gyeongsang National University   (South Korea)

^c Seoul National University Children's Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; GELATIN; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR BB; RESISTIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MOYAMOYA DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHOOL CHILD; STEM CELL; ZYMOGRAPHY;

EID: 77953722773     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.191817     Document Type: Article

References (40)

1. Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol 2008;7:1056-66.
2. Hosoda Y. Pathology of so-called 'spontaneous occlusion of the circle of Willis'. Pathol Annu 1984;19:221-44.
3. Kono S, Oka K, Sueishi K. Histopathologic and morphometric studies of leptomeningeal vessels in moyamoya disease. Stroke 1990;21:1044-50. (Pubitemid 20218169)
4. Hosoda Y, Ikeda E, Hirose S. Histopathological studies on spontaneous occlusion of the circle of Willis (cerebrovascular moyamoya disease). Clin Neurol Neurosurg 1997;99(Suppl 2):203-8.
5. Kang HS, Kim SK, Kim YY, et al. Single nucleotide polymorphisms of tissue inhibitor of metalloproteinase genes in familial moyamoya disease. Neurosurgery 2006;58:1074-80.
6. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000;243:243-55.
7. de Jager W, te Velthuis H, Prakken BJ, et al. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003;10:133-9.
8. Kim JE, Oh CW, Kwon OK, et al. Transient hyperperfusion after superficial temporal artery/middle cerebral artery bypass surgery as a possible cause of postoperative transient neurological deterioration. Cerebrovasc Dis 2008;25:580-6.
9. Fujimura M, Mugikura S, Kaneta T, et al. Incidence and risk factors for symptomatic cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with moyamoya disease. Surg Neurol 2009;71:442-7.
10. Fujimura M, Watanabe M, Narisawa A, et al. Increased expression of serum matrix metalloproteinase-9 in patients with moyamoya disease. Surg Neurol 2009;72:476-80.
11. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005;9:267-85.
12. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008;29:290-308.
13. Johnson C, Galis ZS. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2004;24:54-60.
14. Wu L, Tanimoto A, Murata Y, et al. Matrix metalloproteinase-12 gene expression in human vascular smooth muscle cells. Genes Cells 2003;8:225-34.
15. Pozzi A, LeVine WF, Gardner HA. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002;21:272-81.
16. Ferreras M, Felbor U, Lenhard T, et al. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000;486:247-51.
17. Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003;3:589-601.
18. Sudhakar A, Sugimoto H, Yang C, et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A 2003;100:4766-71.
19. Kallenbach K, Salcher R, Heim A, et al. Inhibition of smooth muscle cell migration and neointima formation in vein grafts by overexpression of matrix metalloproteinase-3. J Vasc Surg 2009;49:750-8.
20. Wu L, Fan J, Matsumoto S, et al. Induction and regulation of matrix metalloproteinase-12 by cytokines and CD40 signaling in monocyte/macrophages. Biochem Biophys Res Commun 2000;269:808-15.
21. Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 1990;11:97-101. (Pubitemid 20062717)
22. Wang L, Li Y, Chen J, et al. Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. Exp Hematol 2002;30:831-6. (Pubitemid 34831705)
23. Fujii T, Yonemitsu Y, Onimaru M, et al. Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2-mediated therapeutic neovascularization: critical role of the inflammatory/arteriogenic pathway. Arterioscler Thromb Vasc Biol 2006;26:2483-9.
24. Capoccia BJ, Gregory AD, Link DC. Recruitment of the inflammatory subset of monocytes to sites of ischemia induces angiogenesis in a monocyte chemoattractant protein-1-dependent fashion. J Leukoc Biol 2008;84:760-8.
25. Demicheva E, Hecker M, Korff T. Stretch-induced activation of the transcription factor activator protein-1 controls monocyte chemoattractant protein-1 expression during arteriogenesis. Circ Res 2008;103:477-84.
26. Muruve DA, Pétrilli V, Zaiss AK, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008;452:103-7.
27. Fearon WF, Fearon DT. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation 2008;117:2577-9.
28. Yamamoto M, Aoyagi M, Fukai N, et al. Increase in prostaglandin E(2) production by interleukin-1beta in arterial smooth muscle cells derived from patients with moyamoya disease. Circ Res 1999;85:912-18.
29. Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 2007;97:714-21.
30. Dorweiler B, Torzewski M, Dahm M, et al. Subendothelial infiltration of neutrophil granulocytes and liberation of matrix-destabilizing enzymes in an experimental model of human neo-intima. Thromb Haemost 2008;99:373-81.
31. Papadopoulou C, Corrigall V, Taylor PR, et al. The role of the chemokines MCP-1, GRO-alpha, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine 2008;43:181-6.
32. Rafat N, Beck GCh, Peña-Tapia PG, et al. Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. Stroke 2009;40:432-8.
33. Kim JH, Jung JH, Phi JH, et al. Decreased level and defective function of circulating endothelial progenitor cells in children with moyamoya disease. J Neurosci Res 2010;88:510-18.
34. Aoyagi M, Fukai N, Sakamoto H, et al. Altered cellular responses to serum mitogens, including platelet-derived growth factor, in cultured smooth muscle cells derived from arteries of patients with moyamoya disease. J Cell Physiol 1991;147:191-8. (Pubitemid 21910098)
35. Aoyagi M, Fukai N, Matsushima Y, et al. Kinetics of 125I-PDGF binding and down-regulation of PDGF receptor in arterial smooth muscle cells derived from patients with moyamoya disease. J Cell Physiol 1993;154:281-8.
36. Yamamoto M, Aoyagi M, Fukai N, et al. Differences in cellular responses to mitogens in arterial smooth muscle cells derived from patients with moyamoya disease. Stroke 1998;29:1188-93. (Pubitemid 28265476)
37. Hoshimaru M, Takahashi JA, Kikuchi H, et al. Possible roles of basic fibroblast growth factor in the pathogenesis of moyamoya disease: an immunohistochemical study. J Neurosurg 1991;75:267-70.
38. Takahashi A, Sawamura Y, Houkin K, et al. The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor. Neurosci Lett 1993;160:214-16.
39. Deguchi Y, Naito T, Yuge T, et al. Blood-brain barrier transport of 125I-labeled basic fibroblast growth factor. Pharm Res 2000;17:63-9.
40. Schweigerer L, Neufeld G, Friedman J, et al. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 1987;325:257-9.